Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro
Molecular and Cellular Endocrinology · 2025
DOI: 10.1016/j.mce.2024.112441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2025. Verfasst von Yilin He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Implant Department, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tiantan Xili No.4, Dongcheng District, Beijin…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Liraglutide, Osteogenesis, Cell Differentiation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
As a GLP-1 receptor agonist widely used in treating type 2 diabetes, liraglutide shows potential applications in bone tissue engineering. This study investigated liraglutide's direct effects on rat bone marrow mesenchymal stem cells (BMSCs) osteogenic differentiation and its regulatory mechanism through macrophage polarization. Results showed that liraglutide significantly enhanced BMSC migration and osteogenic differentiation. Additionally, liraglutide markedly inhibited M1 macrophage polarization induced by LPS and IFN-γ, reducing inflammatory factors CXCL9 and TNF-α secretion, possibly by partially reversing M1 macrophage regulatory signals (AMPK and NF-κB pathways). Compared to M1 macrophage-conditioned medium (M1-CM), conditioned medium from liraglutide-treated macrophages showed stronger promotion of BMSC osteogenic differentiation, though this effect was reversed by CXCL9 addition. The study demonstrates that liraglutide enhances BMSC osteogenic capacity both directly and by inhibiting M1 macrophage polarization and CXCL9 secretion, offering a new therapeutic option for severe bone defects with inflammatory responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Implant Department, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tiantan Xili No.4, Dongcheng District, Beijing, 100050, China.
- Department of Stomatology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
- Department of Stomatology, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, 100039, China.
- Implant Department, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tiantan Xili No.4, Dongcheng District, Beijing, 100050, China. Electronic address: zhenhua_gao@ccmu.edu.cn.
- Implant Department, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Tiantan Xili No.4, Dongcheng District, Beijing, 100050, China. Electronic address: mapanxw@163.com.
Zitieren
APA
He, Y., Song, W., Deng, Y., Lin, X., Gao, Z., & Ma, P. (2025). Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2024.112441
Vancouver
He Y, Song W, Deng Y, Lin X, Gao Z, Ma P. Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro. Molecular and Cellular Endocrinology. 2025. doi:10.1016/j.mce.2024.112441
BibTeX
@article{He2025,
author = {He, Yilin and Song, Wenpeng and Deng, Yinxin and Lin, Xiao and Gao, Zhenhua and Ma, Pan},
title = {Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro},
journal = {Molecular and Cellular Endocrinology},
year = {2025},
doi = {10.1016/j.mce.2024.112441}
}
EUVIMED